BioAffinity Technologies
Open
$2.50
Prev. Close
$2.50
High
$2.50
Low
$2.48
Market Snapshot
$10.93M
-0.7
-0.71
$8.81M
57
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
emptyResult
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Recently from Cashu
BioAffinity Technologies' CyPath® Lung Tool Enhances Lung Cancer Detection for Veterans' Healthcare
Innovative Lung Cancer Detection Tool Gains Traction in Veterans' Healthcare bioAffinity Technologies, Inc., a biotechnology firm focused on noninvasive early-stage cancer detection, gains notable mom…
BioAffinity Technologies Enhances Lung Cancer Detection Access for Veterans with CyPath® Lung Tool
BioAffinity Technologies Expands Access to Lung Cancer Diagnostic Tool for Veterans BioAffinity Technologies, Inc., a biotechnology firm focused on noninvasive early-stage cancer detection, prepares t…
BioAffinity Technologies Appoints Dr. William Bauta as Chief Science Officer for Lung Diagnostics
BioAffinity Technologies Enhances Leadership with Appointment of Dr. William Bauta as Chief Science Officer BioAffinity Technologies, Inc. solidifies its commitment to advancing noninvasive diagnostic…